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questionnaires that were not based on patient interviews. The 25
and 18 item RMDQ is a measure of pain and function widely
used in low back pain (LBP) trials that was based solely on clin-
ician involvement. METHODS: Two US focus groups (n = 15)
and one UK focus group (n = 7) were asked to complete the
problem elicitation technique (PET) alongside the RMDQ to
determine the relevance of items. The PET measures the impor-
tance of concepts based on a series of questions rating the impor-
tance of each item on a ﬁve-point likert response continuum. To
ensure the RMDQ was not missing any relevant items partici-
pants were asked several open-ended questions. RESULTS: Par-
ticipants conﬁrmed the content validity of the RMDQ by
identifying four areas of importance: pain/discomfort, activities
of daily living, sleep problems and emotional impact. Based on
the PET, all RMDQ items were rated as moderately to extremely
important (item score range of 3.57–4.36 on a one—ﬁve scale).
Items rated least important were the same items removed in the
18 item version. In the open ended questions, sleep disturbances
was consistently mentioned as a primary area of concern. CON-
CLUSIONS: The PET augmented by open-ended questions is a
valid method for conﬁrming the content validity of question-
naires that did not include patient involvement in their develop-
ment. These ﬁndings support the continued use of the RMDQ
in LBP trials; however, consideration should be given to includ-
ing additional sleep questions or measuring this concept 
separately.
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OBJECTIVES: To determine whether Home Automated Telem-
anagement (HAT) affects disease-speciﬁc Quality of Life (QOL)
in adult asthma patients. METHODS: Fifty adult patients with
mild persistent to severe asthma were randomly assigned to an
intervention or control group and were followed for 12 months.
The patients in the control group received regular care. The
patients in the intervention group used HAT to monitor and
manage their condition. The HAT system assisted clinicians in
setting up individualized action plans and helped asthma patients
in following their action plans at home using peak ﬂow meter
and a laptop connected with a hospital. RESULTS: Both inter-
vention and control group patients had similar baseline demo-
graphic characteristics with regard to their asthma severity,
action plan use, computer skills and the quality of life. After 12-
month follow-up the mean total QOL score in the intervention
and the control group was 20.2 ± 0.9 and 16.9 ± 1.3 respec-
tively. The difference was signiﬁcant (p < 0.0001) at the alpha
level of 0.05. Analysis of the symptoms domain of the asthma
quality of life showed improved score 5.3 ± 0.4 in the interven-
tion group compared to the control group 4.4 ± 0.6 (p < 0.05).
The activities domain of the QOL showed an improvement in
the activities in the intervention group 5.1 ± 0.2 compared to the
control group 3.7 ± 0.3 (p < 0.05). There was a statistically sig-
niﬁcant difference (p < 0.05) in the emotions domain of the
QOL: the mean score in the intervention group was 4.8 ± 0.2
whereas the mean score in the control group was 4.4 ± 0.4. The
environment domain in the intervention group was 5.1 ± 0.3
compared to 4.4 ± 0.5 in the control group (p < 0.005). CON-
CLUSION: Disease-speciﬁc quality of life in asthma patients is
positively affected by Home Telemanagement.
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OBJECTIVES: To assess health-related quality-of-life (HRQOL)
for patients with chronic obstructive pulmonary disease (COPD).
METHODS: In Spring 2004, 700 patients cared for by pulmo-
nologists or general practitioners at 12 sites across the US com-
pleted a 90-item survey that included the SF-12v2 and
pre-/post-bronchodilator spirometry. COPD was deﬁned as post-
bronchodilator Forced Expiratory Volume in one second/Forced
Vital Capacity (FEV1/FVC) <70%. Descriptive statistics for SF-
12v2 measures were calculated for mild (FEV1 >80% predicted)
and moderate/severe (FEV1 <80% predicted) COPD. Disease
burden was estimated by adjusting general population norma-
tive data from the 1998 National Survey of Functional Health
Status (NSFHS) to age and sex characteristics of the COPD
sample. Multivariate and univariate analyses of variance
(MANOVA, ANOVA) F-statistics were used to test for differ-
ences between patients’ HRQOL and adjusted norms. RESULTS:
Based on spirometry, 36% (N = 249) of patients had COPD
(20% mild, 80% moderate/severe). Patients with COPD were
less likely to describe their health as very good or excellent
(20.5% vs. 36.8%, p < 0.001), and more likely to describe their
health as fair or poor (33.3% vs. 23.4%, p < 0.005) compared
to those without COPD. MANOVA revealed a signiﬁcant dif-
ference between the full proﬁle of SF-12v2 scales for COPD
patients and the US general population (p < 0.001). Adjusted
norm comparisons revealed that patients with mild COPD had
signiﬁcantly lower (mean, SD) Role Physical (41.9, 11.1; p <
0.02) and Physical Component Summary (PCS) (41.0, 12.0; p <
0.02) scores. Moderate/severe COPD patients had large, statisti-
cally signiﬁcant decrements across all SF-12v2 measures. Differ-
ences from normative values were most notable for Physical
Functioning (38.2, 12.8; p < 0.001), PCS (38.9, 11.7; p < 0.001),
Role Physical (39.7, 11.9; p < 0.001), General Health (40.8,
11.2; p < 0.001), and Role Emotional (43.0, 13.0; p < 0.001).
CONCLUSION: Compared to the US general population,
COPD has a signiﬁcant impact on a patient’s HRQOL, notable
with mild disease and pronounced at higher severity levels.
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OBJECTIVES: To explore the cost-effectiveness of ﬂuticasone
propionate (FP) for the treatment of chronic obstructive pul-
monary disease (COPD), we estimated costs and quality adjusted
life years (QALYs) over three-years, based on an economic
appraisal of a previously reported clinical trial (ISOLDE).
METHODS: Results from the initial analyses of the trial data
showed signiﬁcant improvements with FP in reducing the rate of
exacerbations from COPD, in slowing the rate of decline in
health status and a trend towards improved survival. A recently
